Feed BNR
BN

Burning Rock Biotech Limited

BNR · NASDAQ

$12.80 +10.70% (+$1.24)
1M +34.48%
Market Cap ¥90.6M
P/E Ratio -
Div. Yield -
ROE 12.97%
Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/B 0.18x
P/S 0.18x
PEG N/A
Growth
10 /100
Declining
Book val. growth 22.67%
Rev. growth 1.42%
FCF growth N/A
Profitability
20 /100
Weak
FCF margin 7.88%
Op. margin 12.99%
Gross margin 74.55%
Quality
8 /100
Poor
Asset turnover 0.67x
ROA 9.06%
ROIC 12.01%
Debt
69 /100
Low
Current ratio 3.03x
Int. coverage -1,104.23x
Debt/Equity 0.09x
Stability
53 /100
Moderate
Profitable years 0
EPS volatility 50.71%
Beta 1.39x

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BNR
Online

About the company

Burning Rock Biotech Limited (BNR) is a biotechnology company focused on the development and commercialization of diagnostic tests for oncological diseases. Their products include genetic tests and tests for the detection of tumor biomarkers, which help physicians accurately diagnose and treat cancer. Burning Rock Biotech is known for its ability to integrate advanced technologies such as DNA sequencing and artificial intelligence into its diagnostic tests, enabling rapid and precise diagnosis of cancerous diseases. The company also focuses on developing personalized treatment approaches that improve treatment outcomes for cancer patients. Burning Rock Biotech Limited (BNR) shares could be suitable for investors looking for opportunities in the biotechnology sector with an emphasis on cancer diagnosis and treatment.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

CEO

Yusheng Han

Employees

667

Headquarters

Guangzhou

Upcoming events

17 NOV

Earnings

Upcoming earnings report

61d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.